Marex Group plc Announces Launch of a Public Offering
Rhea-AI Summary
Marex Group plc (Nasdaq: MRX) has announced a public offering of ordinary shares by its selling shareholders. The offering consists of 8,500,000 ordinary shares, with an additional 30-day option for underwriters to purchase up to 1,275,000 additional shares.
The company itself is not selling any shares and will not receive any proceeds from the offering. Goldman Sachs & Co. , Barclays, and Jefferies are serving as lead book-running managers for the proposed offering.
The offering will be conducted through a prospectus, and a registration statement has been filed with the SEC, pending effectiveness. The sale of securities cannot commence until the registration statement becomes effective.
Positive
- None.
Negative
- Potential stock price pressure from 8.5 million shares being sold by existing shareholders
- Additional dilution risk from 1,275,000 share overallotment option
- No capital raised for company operations or growth as proceeds go to selling shareholders
News Market Reaction
On the day this news was published, MRX gained 0.08%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (Nasdaq: MRX) (“Marex”), the diversified global financial services platform, today announces the launch of a public offering of its ordinary shares (the "Offering”) by certain selling shareholders (the “Selling Shareholders”). The Selling Shareholders are offering a total of 8,500,000 ordinary shares. In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,275,000 ordinary shares.
Marex is not selling any ordinary shares in the Offering and will not receive any proceeds from the sale of shares by the Selling Shareholders.
Goldman Sachs & Co. LLC, Barclays and Jefferies are acting as lead book-running managers and as representatives of the underwriters for the proposed offering.
The proposed Offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the proposed Offering may be obtained from:
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com;
- Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@broadridge.com; or
- Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Enquiries please contact:
Nicola Ratchford / Adam Strachan
Marex
+44 (0) 778 654 8889 / +1 (914) 200 2508 | nratchford@marex.com / astrachan@marex.com
FTI Consulting US / UK
+1 (919) 609-9423 / +44 (0) 7776 111 222 | marex@fticonsulting.com
FAQ
How many shares are being offered in the Marex Group (MRX) public offering?
Will Marex Group (MRX) receive any proceeds from this share offering?
Who are the lead underwriters for the Marex Group (MRX) public offering?
When will the Marex Group (MRX) share offering become effective?
